Company / Cost of Revenue
Veracyte, Inc. Cost of Revenue History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$36.1M
FY2019
5-year range
-
FY2016-FY2019
Trend
+9.1%
vs FY2018
Sector context
#102 of 107
Health Care
What the data says
Among 107 Health Care companies, Veracyte, Inc. is in the top 5% for cost of revenue. Cost of Revenue has increased for 3 consecutive years, from $25M in FY2016 to $36M in FY2019.
Based on SEC 10-K filings.
$36M in FY2019 with a 3-year CAGR of +12.3%.
Increased from $28M to $36M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +12.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 107This company $36.1M Sector average $11.8B
▼
-99.7% below sector average
Key checks
Key Insights
- Veracyte, Inc.'s cost of revenue has grown for 3 consecutive years.
- 3-year CAGR of +12.3%, indicating consistent growth.
- In FY2019, cost of revenue increased 9.1% year-over-year.
- Ranks #102 out of 107 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $36.1M | +9.1% |
| FY2018 | $33.1M | +17.3% |
| FY2017 | $28.2M | +10.7% |
| FY2016 | $25.5M | +18.4% |
As of FY2019 · SEC 10-K · Updated Feb 28, 2026